4118:TSEKaneka Corporation Analysis
Data as of 2026-06-26 - not real-time
¥5,775.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Kaneka’s share price is trading comfortably above its short‑term and long‑term moving averages, confirming a bullish price trend despite a recent pullback signal from the MACD histogram turning negative.
The momentum indicator sits in overbought territory, suggesting short‑term price pressure may build, while the low beta underscores a defensive profile relative to the market.
Fundamental metrics paint a value‑oriented picture: the price‑to‑earnings multiple is modest, the price‑to‑book ratio is well below one, and the dividend yield is notably high, all of which point to an attractive income stream.
A discounted cash‑flow model places the fair value above the current market price, indicating upside potential, and the company’s cash flow remains solid enough to sustain its dividend payout.
However, the sector’s cyclicality and regulatory environment for specialty chemicals introduce medium‑level risks, and the elevated 30‑day volatility suggests price swings may be sharper than the low beta would imply.
Overall, the stock appears undervalued with a strong dividend foundation, making it a compelling candidate for investors with a medium to long horizon, while short‑term traders may adopt a cautious stance.
The momentum indicator sits in overbought territory, suggesting short‑term price pressure may build, while the low beta underscores a defensive profile relative to the market.
Fundamental metrics paint a value‑oriented picture: the price‑to‑earnings multiple is modest, the price‑to‑book ratio is well below one, and the dividend yield is notably high, all of which point to an attractive income stream.
A discounted cash‑flow model places the fair value above the current market price, indicating upside potential, and the company’s cash flow remains solid enough to sustain its dividend payout.
However, the sector’s cyclicality and regulatory environment for specialty chemicals introduce medium‑level risks, and the elevated 30‑day volatility suggests price swings may be sharper than the low beta would imply.
Overall, the stock appears undervalued with a strong dividend foundation, making it a compelling candidate for investors with a medium to long horizon, while short‑term traders may adopt a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near recent resistance level
- RSI in overbought territory
- Bearish MACD divergence
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF valuation indicates upside
- Attractive dividend yield with sustainable payout
- Low beta and stable cash flow
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Consistent value metrics (low P/E, low P/B)
- Strong dividend track record
- Strategic positioning in specialty chemicals with growth potential
Key Metrics & Analysis
Financial Health
Revenue Growth4.50%
Profit Margin3.82%
P/E Ratio11.6
ROE6.43%
ROA2.10%
Debt/Equity44.34
P/B Ratio0.7
Op. Cash Flow¥50.1B
Free Cash Flow¥-2630749952
Technical Analysis
TrendBullish
RSI62.6
Support¥5,336.00
Resistance¥5,873.00
MA 20¥5,626.35
MA 50¥5,314.16
MA 200¥4,739.82
MACDBearish
VolumeStable
Fear & Greed Index85.45
Valuation
Fair Value¥6,416.71
Target Price¥4,966.67
Upside/Downside-14.00%
GradeUndervalued
TypeValue
Dividend Yield3.64%
Risk Assessment
Beta0.35
Volatility25.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.